{"id":"autologous-cell-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Cytokine release syndrome"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Graft-versus-host disease (if allogeneic)"}]},"_chembl":{"chemblId":"CHEMBL5315093","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The therapy isolates cells from the patient's own body, which are then cultured, expanded, or genetically modified outside the body to enhance their therapeutic properties. These cells are subsequently reintroduced into the patient to repair damaged tissues, replace lost cell populations, or enhance immune function. This approach leverages the patient's own cellular machinery to achieve therapeutic benefit while minimizing rejection risk.","oneSentence":"Autologous cell therapy involves harvesting a patient's own cells, processing or expanding them ex vivo, and reinfusing them to restore function or modulate immune responses.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:42:13.379Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT07488923","phase":"PHASE1","title":"A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs","status":"NOT_YET_RECRUITING","sponsor":"Moonlight Bio, Inc","startDate":"2026-05","conditions":"Small Cell Lung Cancer (SCLC ), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), Gastroenteropancreatic NEC (GEP NEC)","enrollment":110},{"nctId":"NCT03686124","phase":"PHASE1, PHASE2","title":"ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors","status":"RECRUITING","sponsor":"Immatics US, Inc.","startDate":"2019-05-14","conditions":"Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult","enrollment":375},{"nctId":"NCT06413498","phase":"PHASE3","title":"A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2024-08-23","conditions":"Multiple Myeloma","enrollment":450},{"nctId":"NCT06154252","phase":"PHASE2, PHASE3","title":"RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy","status":"RECRUITING","sponsor":"Cabaletta Bio","startDate":"2023-12-20","conditions":"Idiopathic Inflammatory Myopathy, Dermatomyositis, Anti-Synthetase Syndrome","enrollment":74},{"nctId":"NCT07495631","phase":"NA","title":"Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Acute Lymphoblastic Leukemia, Adult","enrollment":80},{"nctId":"NCT01306019","phase":"PHASE1, PHASE2","title":"Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-09-25","conditions":"X-linked Severe Combined Immunodeficiency (XSCID)","enrollment":40},{"nctId":"NCT02443077","phase":"PHASE3","title":"Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-10-12","conditions":"Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type","enrollment":94},{"nctId":"NCT04531046","phase":"PHASE2","title":"Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2021-03-10","conditions":"B-Cell Lymphoma Refractory, B-cell Lymphoma Recurrent","enrollment":62},{"nctId":"NCT03721068","phase":"PHASE1","title":"Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2019-02-19","conditions":"Neuroblastoma, Osteosarcoma","enrollment":18},{"nctId":"NCT05071222","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Transplantation of Autologous CD34+ Cells Transduced With the G2ARTE Lentiviral Vector Expressing the DCLRE1C cDNA in Artemis (DCLRE1C) Deficient Severe Combined Immunodeficiency Patients (ARTEGENE)","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-07-19","conditions":"Artemis (DCLRE1C ) Deficient Severe Combined Immunodeficiency","enrollment":7},{"nctId":"NCT05665166","phase":"PHASE1, PHASE2","title":"Gene Therapy With Modified Autologous Hematopoietic Stem Cells for Patients With Mucopolysaccharidosis Type II","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Manchester","startDate":"2023-06-01","conditions":"Mucopolysaccharidosis II","enrollment":5},{"nctId":"NCT06904066","phase":"PHASE1","title":"Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"Malignancy, Hematologic, Neoplasms, Hematologic, Neoplasms, Hematopoietic","enrollment":86},{"nctId":"NCT04236739","phase":"PHASE3","title":"Comparing Clinical Outcomes of the One-step Cartilage Transplantation in Cartilage Defects of the Knee With Conservative Treatment","status":"COMPLETED","sponsor":"R.J.H. Custers","startDate":"2019-07-23","conditions":"Cartilage Damage","enrollment":60},{"nctId":"NCT05674175","phase":"PHASE1, PHASE2","title":"Co-administration of CART22-65s and huCART19 for B-ALL","status":"RECRUITING","sponsor":"Stephan Grupp MD PhD","startDate":"2023-01-25","conditions":"B-cell Acute Lymphoblastic Leukemia, B Lineage Lymphoblastic Lymphoma","enrollment":93},{"nctId":"NCT06959771","phase":"PHASE1, PHASE2","title":"Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient Study","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-07-16","conditions":"CD40L-HyperIgM Syndrome","enrollment":1},{"nctId":"NCT06060613","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of OBX-115 in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Obsidian Therapeutics, Inc.","startDate":"2023-10-25","conditions":"Tumor Skin, Metastatic Melanoma, Melanoma","enrollment":208},{"nctId":"NCT00644228","phase":"PHASE3","title":"Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-07-28","conditions":"DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma","enrollment":525},{"nctId":"NCT04975698","phase":"PHASE2","title":"HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903","status":"COMPLETED","sponsor":"Catherine Bollard","startDate":"2021-10-25","conditions":"HIV Associated Lymphoma","enrollment":12},{"nctId":"NCT05243797","phase":"PHASE3","title":"Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation","status":"RECRUITING","sponsor":"European Myeloma Network B.V.","startDate":"2022-09-08","conditions":"Multiple Myeloma","enrollment":1594},{"nctId":"NCT07493044","phase":"PHASE1","title":"An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Guangzhou FineImmune Biotechnology Co., LTD.","startDate":"2026-03-20","conditions":"Advanced Hepatocellular Carcinoma (HCC), GPC3 Positive Hepatocellular Carcinoma","enrollment":15},{"nctId":"NCT07493395","phase":"PHASE2","title":"Phase IIa Trial of Anti-CD19 CAR T-Cells in Systemic Sclerosis Resistant to Immunosuppressive Therapy","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2026-04-01","conditions":"Scleroderma, Systemic","enrollment":6},{"nctId":"NCT06767046","phase":"PHASE1","title":"KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Corregene Biotechnology Co., Ltd","startDate":"2025-02-18","conditions":"Colorectal, Pancreatic, Non-small Cell Lung Cancer (NSCLC)","enrollment":8},{"nctId":"NCT02360579","phase":"PHASE2","title":"Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma","status":"COMPLETED","sponsor":"Iovance Biotherapeutics, Inc.","startDate":"2015-09-24","conditions":"Metastatic Melanoma","enrollment":220},{"nctId":"NCT06985498","phase":"PHASE2","title":"Immunotherapy Combined With Auto-HSCT and CD22/CD19 CAR-T Sandwich Strategy for B-ALL","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-06-01","conditions":"Acute Lymphobkastic Leukemia","enrollment":40},{"nctId":"NCT01453088","phase":"PHASE2","title":"Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older","status":"TERMINATED","sponsor":"Hackensack Meridian Health","startDate":"2010-06-24","conditions":"Multiple Myeloma","enrollment":63},{"nctId":"NCT04464434","phase":"PHASE4","title":"Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis","status":"COMPLETED","sponsor":"UMC Utrecht","startDate":"2020-09-17","conditions":"Systemic Sclerosis, Systemic Scleroses, Diffuse, Scleroderma","enrollment":60},{"nctId":"NCT07250269","phase":"PHASE1","title":"Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis","status":"RECRUITING","sponsor":"Gracell Biotechnologies (Shanghai) Co., Ltd.","startDate":"2025-10-29","conditions":"Relapsed/Refractory AL Amyloidosis","enrollment":9},{"nctId":"NCT07490951","phase":"NA","title":"Cluster of Differentiation 19 (CD19)/B Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Refractory Autoimmune Diseases","status":"NOT_YET_RECRUITING","sponsor":"Shenzhen Genocury Biotech Co., Ltd.","startDate":"2026-03-22","conditions":"Autoimmune Diseases","enrollment":20},{"nctId":"NCT06799247","phase":"PHASE3","title":"Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis","status":"RECRUITING","sponsor":"Cartesian Therapeutics","startDate":"2025-05-06","conditions":"Myasthaenia Gravis","enrollment":100},{"nctId":"NCT06163573","phase":"PHASE2","title":"Treatment of Patellofemoral Osteoarthritis With Engineered Cartilage.","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2024-06-06","conditions":"Patellofemoral Osteoarthritis","enrollment":75},{"nctId":"NCT03412877","phase":"PHASE2","title":"Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-09-06","conditions":"Endocrine Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer","enrollment":285},{"nctId":"NCT04268498","phase":"PHASE2","title":"A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2020-02-11","conditions":"Multiple Myeloma","enrollment":310},{"nctId":"NCT06576583","phase":"PHASE2","title":"Implantation of Engineered Cartilage Grafts for Treatment of Patellofemoral Osteoarthritis Versus Surgical Comparators.","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2025-07-15","conditions":"Patellofemoral Osteoarthritis","enrollment":150},{"nctId":"NCT06871410","phase":"PHASE1","title":"Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-03-02","conditions":"Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":26},{"nctId":"NCT05099770","phase":"PHASE3","title":"Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease","status":"RECRUITING","sponsor":"Prokidney","startDate":"2022-01-05","conditions":"Type 2 Diabetes Mellitus, Chronic Kidney Diseases","enrollment":685},{"nctId":"NCT03267433","phase":"PHASE3","title":"Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2017-11-27","conditions":"Mantle Cell Lymphoma","enrollment":689},{"nctId":"NCT02573896","phase":"PHASE1","title":"Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells","status":"ACTIVE_NOT_RECRUITING","sponsor":"New Approaches to Neuroblastoma Therapy Consortium","startDate":"2019-01-14","conditions":"Neuroblastoma","enrollment":13},{"nctId":"NCT07487467","phase":"NA","title":"Autologous SVF Therapy for Type 2 Diabetes","status":"RECRUITING","sponsor":"Kaiser Clinic and Hospital","startDate":"2025-01-20","conditions":"Diabetes Mellitus, Type 2","enrollment":10},{"nctId":"NCT06789081","phase":"EARLY_PHASE1","title":"GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy (GCAR1) for a Patient With Alveolar Soft Part Sarcoma (CLIC-YYC-GPNMB-02)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AHS Cancer Control Alberta","startDate":"2024-02-01","conditions":"Alveolar Soft Part Sarcoma","enrollment":1},{"nctId":"NCT03889834","phase":"NA","title":"Biological Parameters Changes After Autologous Blood Transfusion of Red Blood Cells (200 ml) in Healthy Volunteers.","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-01-25","conditions":"The Focus is on the Detection of the Consequences of Autologous Blood Transfusion in Healthy Volunteers","enrollment":30},{"nctId":"NCT03570892","phase":"PHASE3","title":"Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-05-07","conditions":"Non-Hodgkin Lymphoma","enrollment":331},{"nctId":"NCT02773030","phase":"PHASE1, PHASE2","title":"A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2016-10-14","conditions":"Multiple Myeloma","enrollment":466},{"nctId":"NCT07485647","phase":"PHASE2","title":"Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing","status":"NOT_YET_RECRUITING","sponsor":"Eden Biltibo","startDate":"2026-05","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT05405387","phase":"PHASE2","title":"Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant","status":"RECRUITING","sponsor":"University of Utah","startDate":"2023-05-03","conditions":"Multiple Myeloma, Plasma Cell Leukemia","enrollment":120},{"nctId":"NCT05359211","phase":"PHASE1","title":"NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2022-12-08","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma","enrollment":27},{"nctId":"NCT06158139","phase":"PHASE1","title":"Autologous CAR-T Cells Targeting B7-H3 in PDAC","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2024-07-18","conditions":"Pancreas Cancer, Relapse, Resistant Cancer","enrollment":27},{"nctId":"NCT07481721","phase":"PHASE1","title":"IL13Rα2 CAR-T Cells Secreting Anti-PD-L1 Antibody for Recurrent Malignant Glioma","status":"NOT_YET_RECRUITING","sponsor":"Ming Yang","startDate":"2026-05-01","conditions":"Recurrent Malignant Glioma","enrollment":24},{"nctId":"NCT05828511","phase":"PHASE1, PHASE2","title":"A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-12-19","conditions":"Multiple Myeloma","enrollment":149},{"nctId":"NCT06708455","phase":"PHASE2","title":"Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma","status":"NOT_YET_RECRUITING","sponsor":"Rapa Therapeutics LLC","startDate":"2027-03-01","conditions":"Malignant Melanoma With Metastasis, Malignant Melanoma, Malignant Melanoma Stage IIIc","enrollment":65},{"nctId":"NCT01011920","phase":"PHASE2","title":"Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma","status":"COMPLETED","sponsor":"International Extranodal Lymphoma Study Group (IELSG)","startDate":"2009-11","conditions":"Central Nervous System Lymphoma","enrollment":227},{"nctId":"NCT06071624","phase":"PHASE1","title":"Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.","status":"RECRUITING","sponsor":"Huda Salman","startDate":"2024-02-21","conditions":"Chronic Myelomonocytic Leukemia","enrollment":30},{"nctId":"NCT07479797","phase":"PHASE3","title":"Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy","status":"NOT_YET_RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2026-08","conditions":"Relapsed or Refractory Large B-cell Lymphoma (r/r LBCL)","enrollment":550},{"nctId":"NCT04931368","phase":"PHASE3","title":"OptiMATe: De-escalated Induction Treatment in Primary CNS Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Klinikum Stuttgart","startDate":"2021-06-28","conditions":"Primary Central Nervous System Lymphoma","enrollment":331},{"nctId":"NCT07476183","phase":"PHASE1","title":"Assessing the Safety, Tolerability, and Efficacy of APR-2020 in Pediatric and Adolescent Subjects With RPS19 Deficient Diamond-Blackfan Anemia","status":"NOT_YET_RECRUITING","sponsor":"Apriligen, Inc.","startDate":"2026-03","conditions":"RPS19 Deficient Diamond-Blackfan Anemia","enrollment":4},{"nctId":"NCT04119024","phase":"PHASE1","title":"Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Anusha Kalbasi","startDate":"2025-10-07","conditions":"Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8","enrollment":18},{"nctId":"NCT05257083","phase":"PHASE3","title":"A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting European Myeloma Network","startDate":"2023-10-10","conditions":"Multiple Myeloma","enrollment":759},{"nctId":"NCT05909527","phase":"PHASE1, PHASE2","title":"A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma","status":"WITHDRAWN","sponsor":"Guangzhou Bio-gene Technology Co., Ltd","startDate":"2023-05-01","conditions":"T-Cell Acute Lymphocytic Leukemia","enrollment":""},{"nctId":"NCT07455071","phase":"NA","title":"A Single-center, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Tumor Neoantigen-pulsed Autologous Dendritic Cell Injection (YS247) in Study Participants With HRD-negative Epithelial Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2026-03-01","conditions":"HRD-negative Epithelial Ovarian Cancer","enrollment":9},{"nctId":"NCT07475182","phase":"EARLY_PHASE1","title":"Exploratory Clinical Study of Targeted Activated DC and CAR-T Therapy in Advanced Solid Cancers","status":"RECRUITING","sponsor":"Hainan Cancer Hospital","startDate":"2025-12-06","conditions":"Advanced Solid Cancers","enrollment":10},{"nctId":"NCT07038447","phase":"PHASE1","title":"A Study of KITE-363 in Participants With Refractory Autoimmune Diseases","status":"ENROLLING_BY_INVITATION","sponsor":"Kite, A Gilead Company","startDate":"2025-07-02","conditions":"Systemic Lupus Erythematosus, Lupus Nephritis, Systemic Sclerosis","enrollment":52},{"nctId":"NCT06483048","phase":"PHASE1","title":"MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-09-20","conditions":"Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma","enrollment":12},{"nctId":"NCT06561425","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Galapagos NV","startDate":"2022-03-09","conditions":"Relapsed/Refractory B-cell Non-Hodgkin Lymphoma, Lymphomas Non-Hodgkin&Amp;Amp;#39;s B-Cell","enrollment":130},{"nctId":"NCT05478837","phase":"PHASE1","title":"Genetically Modified Cells (KIND T Cells) for the Treatment of HLA-A*0201-Positive Patients With H3.3K27M-Mutated Glioma","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2023-07-20","conditions":"Diffuse Midline Glioma, H3 K27M-Mutant","enrollment":12},{"nctId":"NCT07473154","phase":"PHASE1, PHASE2","title":"Controlling Hyperactive Immunity With Long-lived Lymphocytes","status":"NOT_YET_RECRUITING","sponsor":"Quell Therapeutics Limited","startDate":"2026-04","conditions":"Diffuse Cutaneous Systemic Sclerosis, Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc)","enrollment":16},{"nctId":"NCT07285694","phase":"PHASE1, PHASE2","title":"AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)","status":"RECRUITING","sponsor":"Arsenal Biosciences, Inc.","startDate":"2026-01-09","conditions":"Metastatic Castration Resistant Prostate Cancer (mCRPC)","enrollment":190},{"nctId":"NCT03392987","phase":"PHASE2","title":"A Safety and Efficacy Study of Cryopreserved OTL-200 for Treatment of Metachromatic Leukodystrophy (MLD)","status":"COMPLETED","sponsor":"Orchard Therapeutics","startDate":"2018-01-25","conditions":"Lysosomal Storage Disease, Metachromatic Leukodystrophy","enrollment":10},{"nctId":"NCT07474467","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Autologous Adipose-derived Mesenchymal Stem Cells Therapy in Adults With Atrophic Scars","status":"NOT_YET_RECRUITING","sponsor":"CellinCells","startDate":"2026-08-01","conditions":"Atrophic Scar","enrollment":31},{"nctId":"NCT06186401","phase":"PHASE1","title":"Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells","status":"RECRUITING","sponsor":"Hideho Okada, MD, PhD","startDate":"2024-04-30","conditions":"EGFR Gene Mutation, Glioblastoma, MGMT-Unmethylated Glioblastoma","enrollment":20},{"nctId":"NCT05784441","phase":"PHASE1","title":"A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-11-06","conditions":"Relapsed or Refractory B Cell Non-Hodgkin Lymphoma","enrollment":21},{"nctId":"NCT00107289","phase":"PHASE2","title":"Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2006-05","conditions":"Neuroblastoma, Pheochromocytoma","enrollment":200},{"nctId":"NCT07471789","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).","status":"RECRUITING","sponsor":"Gyala Therapeutics","startDate":"2026-02-04","conditions":"Acute Myeloblastic Leukaemia, Leukemia, T-Cell","enrollment":33},{"nctId":"NCT05647213","phase":"PHASE1","title":"Autologous Induced Pluripotent Stem Cells of Cardiac Lineage for Congenital Heart Disease","status":"RECRUITING","sponsor":"HeartWorks, Inc.","startDate":"2023-02-03","conditions":"Univentricular Heart, Congenital Heart Disease, Heart Failure NYHA Class III","enrollment":50},{"nctId":"NCT03901963","phase":"PHASE3","title":"A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-04-26","conditions":"Multiple Myeloma","enrollment":200},{"nctId":"NCT06946680","phase":"PHASE1","title":"IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Pediatric High-grade Glioma (HGG)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2025-03-18","conditions":"High-grade Glioma","enrollment":18},{"nctId":"NCT05421663","phase":"PHASE1, PHASE2","title":"A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-08-12","conditions":"Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse","enrollment":439},{"nctId":"NCT03104517","phase":"PHASE3","title":"Autologous Muscle Derived Cells Compared to Placebo for Urinary Sphincter Repair in Post-surgical Female Stress Incontinence","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cook MyoSite","startDate":"2019-04-23","conditions":"Stress Urinary Incontinence","enrollment":96},{"nctId":"NCT05018416","phase":"PHASE2","title":"Renal Autologous Cell Therapy (REACT) in Subjects With Type 1 or 2 Diabetes and Chronic Kidney Disease (REGEN-007)","status":"COMPLETED","sponsor":"Prokidney","startDate":"2021-07-27","conditions":"Chronic Kidney Diseases, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus","enrollment":53},{"nctId":"NCT05827016","phase":"PHASE3","title":"A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2023-06-22","conditions":"Multiple Myeloma","enrollment":1216},{"nctId":"NCT04749667","phase":"PHASE1, PHASE2","title":"Study of Mesenchymal Autologous Stem Cells as Regenerative Treatment for Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Haukeland University Hospital","startDate":"2021-08-09","conditions":"Multiple Sclerosis, Progressive Multiple Sclerosis","enrollment":18},{"nctId":"NCT05767359","phase":"PHASE2","title":"CAR- PRISM (PRecision Intervention Smoldering Myeloma)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2023-04-19","conditions":"Multiple Myeloma, Smoldering Multiple Myeloma","enrollment":20},{"nctId":"NCT05552222","phase":"PHASE3","title":"A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-10-25","conditions":"Multiple Myeloma","enrollment":1590},{"nctId":"NCT07391657","phase":"PHASE3","title":"A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-02-23","conditions":"Relapsed Refractory Multiple Myeloma","enrollment":508},{"nctId":"NCT05651997","phase":"NA","title":"Study Comparing Two Methods for the Treatment of Large Chondral and Osteochondral Defects of the Knee","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2026-12","conditions":"Articular Cartilage Defect, Chondral Defect, Osteochondritis","enrollment":80},{"nctId":"NCT07461831","phase":"PHASE2","title":"CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Beijing Tongren Hospital","startDate":"2022-02-01","conditions":"Large B-Cell Lymphoma (LBCL)","enrollment":100},{"nctId":"NCT05679895","phase":"PHASE1","title":"Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL","status":"RECRUITING","sponsor":"OneChain Immunotherapeutics","startDate":"2023-01-31","conditions":"T-cell Acute Lymphoblastic Leukemia, Lymphoblastic T-Cell Lymphoma","enrollment":20},{"nctId":"NCT04819841","phase":"PHASE1, PHASE2","title":"Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease","status":"RECRUITING","sponsor":"Kamau Therapeutics","startDate":"2021-11-15","conditions":"Sickle Cell Disease","enrollment":15},{"nctId":"NCT05535855","phase":"PHASE1","title":"UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2024-01-24","conditions":"Acute Lymphoid Leukemia, Acute Lymphoblastic Leukemia","enrollment":29},{"nctId":"NCT00492050","phase":"PHASE2","title":"Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-08-02","conditions":"Waldenstrom's Macroglobulinemia","enrollment":46},{"nctId":"NCT04296487","phase":"NA","title":"Introduction of ACI for Cartilage Repair","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2017-09-01","conditions":"Articular Cartilage Defect, Chondral Defect, Osteochondritis","enrollment":218},{"nctId":"NCT01410019","phase":"PHASE1, PHASE2","title":"Gene Therapy for X-linked Severe Combined Immunodeficiency","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2010-12","conditions":"X-linked Severe Combined Immunodeficiency","enrollment":5},{"nctId":"NCT02213913","phase":"PHASE1, PHASE2","title":"Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2014-07-29","conditions":"Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Diffuse Large Cell Lymphoma","enrollment":55},{"nctId":"NCT06345495","phase":"PHASE2","title":"High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-10-01","conditions":"Splenomegaly, Myelofibrosis","enrollment":30},{"nctId":"NCT07465198","phase":"PHASE2","title":"Autologous Stem Cell Therapy in Patients With Multiple System Atrophy","status":"NOT_YET_RECRUITING","sponsor":"Biocells Medical","startDate":"2026-09-01","conditions":"MSA - Multiple System Atrophy, MSA","enrollment":50},{"nctId":"NCT07464951","phase":"PHASE1","title":"CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Stephan Grupp MD PhD","startDate":"2026-04-01","conditions":"Acute Myeloid Leukemia (AML)","enrollment":30},{"nctId":"NCT06193759","phase":"PHASE1","title":"Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)","status":"RECRUITING","sponsor":"Children's National Research Institute","startDate":"2024-09-20","conditions":"Medulloblastoma, Childhood, Atypical Teratoid/Rhabdoid Tumor of CNS, Embryonal Tumor With Multilayered Rosettes","enrollment":12},{"nctId":"NCT07214974","phase":"EARLY_PHASE1","title":"Mild Cognitive Impairment Community Screening and Early Intervention Via Stem Cell Therapy and Wearable Brain Computer Interface Device.","status":"NOT_YET_RECRUITING","sponsor":"Noah Tech, Corp.","startDate":"2026-09-01","conditions":"Mild Cognitive Impairment (MCI), Early Stages of Cognitive Decline, Alzheimer's Disease Dementia","enrollment":600},{"nctId":"NCT07304154","phase":"PHASE1","title":"A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases","status":"NOT_YET_RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2026-03","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy, Myasthenia Gravis, Multiple Sclerosis","enrollment":52},{"nctId":"NCT06326021","phase":"PHASE1","title":"Optimised CD33 (FL-33) CAR T Therapy for Refractory/Relapsed Acute Myeloid Leukaemia","status":"RECRUITING","sponsor":"Beijing GoBroad Hospital","startDate":"2024-04-02","conditions":"Refractory/Relapsed Acute Myeloid Leukaemia","enrollment":27},{"nctId":"NCT05353530","phase":"PHASE1","title":"IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2023-07-25","conditions":"Glioblastoma Multiforme, Glioblastoma","enrollment":39},{"nctId":"NCT07238062","phase":"","title":"\"An Intermediate Size Patient Population Expanded Access Protocol to Evaluate the Safety and Efficacy of Allogeneic HB-adMSCs (Hope Biosciences - Adipose Derived Mesenchymal Stem Cells) for the Treatment of Multiple System Atrophy.\"","status":"TEMPORARILY_NOT_AVAILABLE","sponsor":"Hope Biosciences Research Foundation","startDate":"","conditions":"Multiple System Atrophy","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Autologous cell therapy","genericName":"Autologous cell therapy","companyName":"Dr. Grant M. Pagdin","companyId":"dr-grant-m-pagdin","modality":"Biologic","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":false,"safety":true,"trials":true,"score":3}}